PUBLISHER: TechSci Research | PRODUCT CODE: 1152254
PUBLISHER: TechSci Research | PRODUCT CODE: 1152254
Precision Psychiatry Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027 Segmented By Biomarkers, By Sample, By Technology, By Application, By End User, By Company and By Region
We offer 8 hour analyst time for an additional research. Please contact us for the details.
The global precision psychiatry market is anticipated to observe impressive growth during the forecast period, 2023-2027. The major factors include rise in incidences of mental health and technological advancements, which are bolstering the market growth, globally. Precision psychiatry is new field within precision medicine, which seeks to detect and capitalize on individual differences in biology, environment, lifestyle, and social determinants of health to improve mental health prevention, diagnosis, and treatment. The other factors supporting the market's growth are increasing awareness, growing investments, increase in population, changing lifestyle, decreasing cost of sequencing, increasing adoption of inorganic growth strategies and support from governments for healthcare infrastructure. Also, the high adoption of advanced molecular diagnostic technologies by the researchers to conduct genomic and proteomic analysis associated to the onset and manifestation of psychiatric illnesses are some of the key factors that are projected to bolster the market growth.
Increase in Prevalence of Mental Disorders
Over the past few years, rise in number of people suffering from mild or severe depressive disorders is seen. These mental illness or disorders are basically caused due to chemical, genetic, and anatomical conditions, or psychological origins such as trauma. Thus, to seek better lives for those suffering from mental illness, precision psychiatry is much required, which attributes to the growth of the market, globally. For instance, according to the National Institute of Mental Health, around one in every five U.S. adults suffer from mental illness. Also, in 2020, 25.8% of females were suffering from mental illness.
Increasing Adoption of Inorganic Growth Strategies
Increasing inorganic growth strategies by key players are expected to drive the global precision psychiatry market growth during the forecast period. For instance, in 2021, Alto Neuroscience announced its emergence from stealth with $40 million in funding to advance the largest clinical-stage pipeline of precision psychiatry medicines. Similarly, in 2021, Atai Life Sciences, a biotech company in the psychedelics space, announced the formation of a new subsidiary, called PsyProtix, which is a precision psychiatry company.
Increased demand for Genomics as precision psychiatry
From past few years, genomic technologies have advanced the understanding of neuropsychiatric disorders. Genomics plays a significant part in the diagnosis of several genetic disorders. It has ample scope in precision psychiatry as it can advocate medical management constructed on the genetic face of a person with the help of clinical data and AI. It incorporates DNA sequencing methods, recombinant DNA, and bioinformatics for sequencing, assembling, and analyzing the structure and functions of genomes. Many severe mental illnesses, such as schizophrenia and bipolar disorder, are highly inherited, and have a complex pattern of inheritance. These diseases can be identified by using sequencing technology, which evaluates the rare genetic variants. With the use of sequencing technology, psychiatry can ultimately reshape by predicting disease risk and lead to better understanding of aetiology, prognosis, or treatment response. Moreover, the decrease in cost of sequencing is also a key factor to increase the growth of the market.
Market Segmentation
The global precision psychiatry market is segmented into biomarkers, sample, technology, application, end user, and company. Based on biomarker, the market is divided into genetic and protein. Based on sample, the market is divided into blood-based and non-blood-based. Based on non-blood-based, the market is further divided into saliva, urine, cerebral spinal fluid, and others. Based on technology, the market is divided into sequencing, polymerase chain reaction, microarray, immunoassay, and others. Based on application, the market is divided into Alzheimer's disease, Parkinson's disease, autism, depression, and others. Based on end user, the market is divided into hospital & clinics, academic & research institutions, and others. In terms of country, the United States is expected to be a lucrative market in the forecast period due to rise in incidences of mental illness in the country.
Market Players
Altimate Healthcare, PsyProtix, Inc, Cerebral-Alto Nanoscience, Precision Psychiatric Services, Inc, Tempus Labs, Inc., and Curis AI Inc. are some of the leading companies operating in the market.
Report Scope:
In this report, global precision psychiatry market has been segmented into following categories, in addition to the industry trends which have also been detailed below:
Precision Psychiatry Market, By Biomarker:
- Genetic
- Protein
Precision Psychiatry Market, By Sample:
- Blood Based
- Non-Blood-Based
- Saliva
- Urine
- Cerebral Spinal Fluid
- Others
- Precision Psychiatry Market, By Technology:
- Sequencing
- Polymerase Chain Reaction
- Microarray
- Immunoassay
- Others
Precision Psychiatry Market, By Application:
- Alzheimer's Disease
- Parkinson's Disease
- Autism
- Depression
- Others
Precision Psychiatry Market, By End User:
- Hospital & Clinics
- Academic & Research Institutions
- Others
Precision Psychiatry Market, By Region:
- North America
- United States
- Canada
- Mexico
- Asia-Pacific
- China
- India
- Japan
- Australia
- South Korea
- Europe & CIS
- Germany
- France
- United Kingdom
- Spain
- Italy
- South America
- Brazil
- Argentina
- Colombia
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in precision psychiatry market
Available Customizations:
With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up to five).
Table of Contents
1. Product Overview
2. Research Methodology
3. Executive Summary
4. Impact of COVID-19 on Global Precision Psychiatry Market
5. Voice of Customer
6. Global Precision Psychiatry Market Outlook
- 6.1. Market Size & Forecast
- 6.1.1. By Value
- 6.2. Market Share & Forecast
- 6.2.1. By Biomarkers (Genetic v/s Protein)
- 6.2.2. By Sample (Blood Based v/s Non-Blood-Based)
- 6.2.2.1. By Non-Blood-Based (Saliva, Urine, Cerebral Spinal Fluid, Others)
- 6.2.3. By Technology (Sequencing, Polymerase Chain Reaction, Microarray, Immunoassay, Others)
- 6.2.4. By Application (Alzheimer's Disease, Parkinson's Disease, Autism, Depression, Others)
- 6.2.5. By End User (Hospital & Clinics, Academic & Research Institutions, Others)
- 6.2.6. By Company (2021)
- 6.2.7. By Region
- 6.3. Product Market Map
7. North America Precision Psychiatry Market Outlook
- 7.1. Market Size & Forecast
- 7.1.1. By Value
- 7.2. Market Share & Forecast
- 7.2.1. By Biomarkers (Genetic v/s Protein)
- 7.2.2. By Sample (Blood Based v/s Non-Blood-Based)
- 7.2.2.1. By Non-Blood-Based (Saliva, Urine, Cerebral Spinal Fluid, Others)
- 7.2.3. By Technology (Sequencing, Polymerase Chain Reaction, Microarray, Immunoassay, Others)
- 7.2.4. By Application (Alzheimer's Disease, Parkinson's Disease, Autism, Depression, Others)
- 7.2.5. By End User (Hospital & Clinics, Academic & Research Institutions, Others)
- 7.2.6. By Country
- 7.3. North America: Country Analysis
- 7.3.1. United States Precision Psychiatry Market Outlook
- 7.3.1.1. Market Size & Forecast
- 7.3.1.1.1. By Value
- 7.3.1.2. Market Share & Forecast
- 7.3.1.2.1. By Biomarker
- 7.3.1.2.2. By Sample
- 7.3.1.2.3. By Technology
- 7.3.1.2.4. By Application
- 7.3.1.2.5. By End User
- 7.3.1.1. Market Size & Forecast
- 7.3.2. Mexico Precision Psychiatry Market Outlook
- 7.3.2.1. Market Size & Forecast
- 7.3.2.1.1. By Value
- 7.3.2.2. Market Share & Forecast
- 7.3.2.2.1. By Biomarker
- 7.3.2.2.2. By Sample
- 7.3.2.2.3. By Technology
- 7.3.2.2.4. By Application
- 7.3.2.2.5. By End User
- 7.3.2.1. Market Size & Forecast
- 7.3.3. Canada Precision Psychiatry Market Outlook
- 7.3.3.1. Market Size & Forecast
- 7.3.3.1.1. By Value
- 7.3.3.2. Market Share & Forecast
- 7.3.3.2.1. By Biomarker
- 7.3.3.2.2. By Sample
- 7.3.3.2.3. By Technology
- 7.3.3.2.4. By Application
- 7.3.3.2.5. By End User
- 7.3.3.1. Market Size & Forecast
- 7.3.1. United States Precision Psychiatry Market Outlook
8. Europe Precision Psychiatry Market Outlook
- 8.1. Market Size & Forecast
- 8.1.1. By Value
- 8.2. Market Share & Forecast
- 8.2.1. By Biomarkers (Genetic v/s Protein)
- 8.2.2. By Sample (Blood Based v/s Non-Blood-Based)
- 8.2.2.1. By Non-Blood-Based (Saliva, Urine, Cerebral Spinal Fluid, Others)
- 8.2.3. By Technology (Sequencing, Polymerase Chain Reaction, Microarray, Immunoassay, Others)
- 8.2.4. By Application (Alzheimer's Disease, Parkinson's Disease, Autism, Depression, Others)
- 8.2.5. By End User (Hospital & Clinics, Academic & Research Institutions, Others)
- 8.2.6. By Country
- 8.3. Europe: Country Analysis
- 8.3.1. France Precision Psychiatry Market Outlook
- 8.3.1.1. Market Size & Forecast
- 8.3.1.1.1. By Value
- 8.3.1.2. Market Share & Forecast
- 8.3.1.2.1. By Biomarker
- 8.3.1.2.2. By Sample
- 8.3.1.2.3. By Technology
- 8.3.1.2.4. By Application
- 8.3.1.2.5. By End User
- 8.3.1.1. Market Size & Forecast
- 8.3.2. Germany Precision Psychiatry Market Outlook
- 8.3.2.1. Market Size & Forecast
- 8.3.2.1.1. By Value
- 8.3.2.2. Market Share & Forecast
- 8.3.2.2.1. By Biomarker
- 8.3.2.2.2. By Sample
- 8.3.2.2.3. By Technology
- 8.3.2.2.4. By Application
- 8.3.2.2.5. By End User
- 8.3.2.1. Market Size & Forecast
- 8.3.3. United Kingdom Precision Psychiatry Market Outlook
- 8.3.3.1. Market Size & Forecast
- 8.3.3.1.1. By Value
- 8.3.3.2. Market Share & Forecast
- 8.3.3.2.1. By Biomarker
- 8.3.3.2.2. By Sample
- 8.3.3.2.3. By Technology
- 8.3.3.2.4. By Application
- 8.3.3.2.5. By End User
- 8.3.3.1. Market Size & Forecast
- 8.3.4. Italy Precision Psychiatry Market Outlook
- 8.3.4.1. Market Size & Forecast
- 8.3.4.1.1. By Value
- 8.3.4.2. Market Share & Forecast
- 8.3.4.2.1. By Biomarker
- 8.3.4.2.2. By Sample
- 8.3.4.2.3. By Technology
- 8.3.4.2.4. By Application
- 8.3.4.2.5. By End User
- 8.3.4.1. Market Size & Forecast
- 8.3.5. Spain Precision Psychiatry Market Outlook
- 8.3.5.1. Market Size & Forecast
- 8.3.5.1.1. By Value
- 8.3.5.2. Market Share & Forecast
- 8.3.5.2.1. By Biomarker
- 8.3.5.2.2. By Sample
- 8.3.5.2.3. By Technology
- 8.3.5.2.4. By Application
- 8.3.5.2.5. By End User
- 8.3.5.1. Market Size & Forecast
- 8.3.1. France Precision Psychiatry Market Outlook
9. Asia-Pacific Precision Psychiatry Market Outlook
- 9.1. Market Size & Forecast
- 9.1.1. By Value
- 9.2. Market Share & Forecast
- 9.2.1. By Biomarkers (Genetic v/s Protein)
- 9.2.2. By Sample (Blood Based v/s Non-Blood-Based)
- 9.2.2.1. By Non-Blood-Based (Saliva, Urine, Cerebral Spinal Fluid, Others)
- 9.2.3. By Technology (Sequencing, Polymerase Chain Reaction, Microarray, Immunoassay, Others)
- 9.2.4. By Application (Alzheimer's Disease, Parkinson's Disease, Autism, Depression, Others)
- 9.2.5. By End User (Hospital & Clinics, Academic & Research Institutions, Others)
- 9.2.6. By Country
- 9.3. Asia-Pacific: Country Analysis
- 9.3.1. China Precision Psychiatry Market Outlook
- 9.3.1.1. Market Size & Forecast
- 9.3.1.1.1. By Value
- 9.3.1.2. Market Share & Forecast
- 9.3.1.2.1. By Biomarker
- 9.3.1.2.2. By Sample
- 9.3.1.2.3. By Technology
- 9.3.1.2.4. By Application
- 9.3.1.2.5. By End User
- 9.3.1.1. Market Size & Forecast
- 9.3.2. India Precision Psychiatry Market Outlook
- 9.3.2.1. Market Size & Forecast
- 9.3.2.1.1. By Value
- 9.3.2.2. Market Share & Forecast
- 9.3.2.2.1. By Biomarker
- 9.3.2.2.2. By Sample
- 9.3.2.2.3. By Technology
- 9.3.2.2.4. By Application
- 9.3.2.2.5. By End User
- 9.3.2.1. Market Size & Forecast
- 9.3.3. South Korea Precision Psychiatry Market Outlook
- 9.3.3.1. Market Size & Forecast
- 9.3.3.1.1. By Value
- 9.3.3.2. Market Share & Forecast
- 9.3.3.2.1. By Biomarker
- 9.3.3.2.2. By Sample
- 9.3.3.2.3. By Technology
- 9.3.3.2.4. By Application
- 9.3.3.2.5. By End User
- 9.3.3.1. Market Size & Forecast
- 9.3.4. Japan Precision Psychiatry Market Outlook
- 9.3.4.1. Market Size & Forecast
- 9.3.4.1.1. By Value
- 9.3.4.2. Market Share & Forecast
- 9.3.4.2.1. By Biomarker
- 9.3.4.2.2. By Sample
- 9.3.4.2.3. By Technology
- 9.3.4.2.4. By Application
- 9.3.4.2.5. By End User
- 9.3.4.1. Market Size & Forecast
- 9.3.5. Australia Precision Psychiatry Market Outlook
- 9.3.5.1. Market Size & Forecast
- 9.3.5.1.1. By Value
- 9.3.5.2. Market Share & Forecast
- 9.3.5.2.1. By Biomarker
- 9.3.5.2.2. By Sample
- 9.3.5.2.3. By Technology
- 9.3.5.2.4. By Application
- 9.3.5.2.5. By End User
- 9.3.5.1. Market Size & Forecast
- 9.3.1. China Precision Psychiatry Market Outlook
10. South America Precision Psychiatry Market Outlook
- 10.1. Market Size & Forecast
- 10.1.1. By Value
- 10.2. Market Share & Forecast
- 10.2.1. By Biomarkers (Genetic v/s Protein)
- 10.2.2. By Sample (Blood Based v/s Non-Blood-Based)
- 10.2.2.1. By Non-Blood-Based (Saliva, Urine, Cerebral Spinal Fluid, Others)
- 10.2.3. By Technology (Sequencing, Polymerase Chain Reaction, Microarray, Immunoassay, Others)
- 10.2.4. By Application (Alzheimer's Disease, Parkinson's Disease, Autism, Depression, Others)
- 10.2.5. By End User (Hospital & Clinics, Academic & Research Institutions, Others)
- 10.2.6. By Country
- 10.3. South America: Country Analysis
- 10.3.1. Brazil Precision Psychiatry Market Outlook
- 10.3.1.1. Market Size & Forecast
- 10.3.1.1.1. By Value
- 10.3.1.2. Market Share & Forecast
- 10.3.1.2.1. By Biomarker
- 10.3.1.2.2. By Sample
- 10.3.1.2.3. By Technology
- 10.3.1.2.4. By Application
- 10.3.1.2.5. By End User
- 10.3.1.1. Market Size & Forecast
- 10.3.2. Argentina Precision Psychiatry Market Outlook
- 10.3.2.1. Market Size & Forecast
- 10.3.2.1.1. By Value
- 10.3.2.2. Market Share & Forecast
- 10.3.2.2.1. By Biomarker
- 10.3.2.2.2. By Sample
- 10.3.2.2.3. By Technology
- 10.3.2.2.4. By Application
- 10.3.2.2.5. By End User
- 10.3.2.1. Market Size & Forecast
- 10.3.3. Colombia Precision Psychiatry Market Outlook
- 10.3.3.1. Market Size & Forecast
- 10.3.3.1.1. By Value
- 10.3.3.2. Market Share & Forecast
- 10.3.3.2.1. By Biomarker
- 10.3.3.2.2. By Sample
- 10.3.3.2.3. By Technology
- 10.3.3.2.4. By Application
- 10.3.3.2.5. By End User
- 10.3.3.1. Market Size & Forecast
- 10.3.1. Brazil Precision Psychiatry Market Outlook
11. Middle East and Africa Precision Psychiatry Market Outlook
- 11.1. Market Size & Forecast
- 11.1.1. By Value
- 11.2. Market Share & Forecast
- 11.2.1. By Biomarkers (Genetic v/s Protein)
- 11.2.2. By Sample (Blood Based v/s Non-Blood-Based)
- 11.2.2.1. By Non-Blood-Based (Saliva, Urine, Cerebral Spinal Fluid, Others)
- 11.2.3. By Technology (Sequencing, Polymerase Chain Reaction, Microarray, Immunoassay, Others)
- 11.2.4. By Application (Alzheimer's Disease, Parkinson's Disease, Autism, Depression, Others)
- 11.2.5. By End User (Hospital & Clinics, Academic & Research Institutions, Others)
- 11.2.6. By Country
- 11.3. MEA: Country Analysis
- 11.3.1. South Africa Precision Psychiatry Market Outlook
- 11.3.1.1. Market Size & Forecast
- 11.3.1.1.1. By Value
- 11.3.1.2. Market Share & Forecast
- 11.3.1.2.1. By Biomarker
- 11.3.1.2.2. By Sample
- 11.3.1.2.3. By Technology
- 11.3.1.2.4. By Application
- 11.3.1.2.5. By End User
- 11.3.1.1. Market Size & Forecast
- 11.3.2. Saudi Arabia Precision Psychiatry Market Outlook
- 11.3.2.1. Market Size & Forecast
- 11.3.2.1.1. By Value
- 11.3.2.2. Market Share & Forecast
- 11.3.2.2.1. By Biomarker
- 11.3.2.2.2. By Sample
- 11.3.2.2.3. By Technology
- 11.3.2.2.4. By Application
- 11.3.2.2.5. By End User
- 11.3.2.1. Market Size & Forecast
- 11.3.3. UAE Precision Psychiatry Market Outlook
- 11.3.3.1. Market Size & Forecast
- 11.3.3.1.1. By Value
- 11.3.3.2. Market Share & Forecast
- 11.3.3.2.1. By Biomarker
- 11.3.3.2.2. By Sample
- 11.3.3.2.3. By Technology
- 11.3.3.2.4. By Application
- 11.3.3.2.5. By End User
- 11.3.3.1. Market Size & Forecast
- 11.3.4. Egypt Precision Psychiatry Market Outlook
- 11.3.4.1. Market Size & Forecast
- 11.3.4.1.1. By Value
- 11.3.4.2. Market Share & Forecast
- 11.3.4.2.1. By Biomarker
- 11.3.4.2.2. By Sample
- 11.3.4.2.3. By Technology
- 11.3.4.2.4. By Application
- 11.3.4.2.5. By End User
- 11.3.4.1. Market Size & Forecast
- 11.3.5. Turkey Precision Psychiatry Market Outlook
- 11.3.5.1. Market Size & Forecast
- 11.3.5.1.1. By Value
- 11.3.5.2. Market Share & Forecast
- 11.3.5.2.1. By Biomarker
- 11.3.5.2.2. By Sample
- 11.3.5.2.3. By Technology
- 11.3.5.2.4. By Application
- 11.3.5.2.5. By End User
- 11.3.5.1. Market Size & Forecast
- 11.3.1. South Africa Precision Psychiatry Market Outlook
12. Market Dynamics
- 12.1. Drivers
- 12.2. Challenges
13. Market Trends & Developments
14. Competitive Landscape
- 14.1. Altimate Healthcare
- 14.2. PsyProtix, Inc
- 14.3. Cerebral-Alto Nanoscience
- 14.4. Precision Psychiatric Services, Inc
- 14.5. Tempus Labs, Inc.
- 14.6. Curis AI Inc.
15. Strategic Recommendations
